Date Field | Doc. No. | Party | Description |
---|
Mar 24, 2017 | 1 | | Pfizer, Inc.s Power of Attorney Download |
Mar 24, 2017 | 2 | | PETITION FOR INTER PARTES REVIEW Download |
Mar 24, 2017 | 3 | | MOTION FOR JOINDER Download |
Apr 6, 2017 | 4 | | Notice of Defective Petition Download |
Apr 11, 2017 | 5 | | Notice of Accepting Corrected Petition Download |
Apr 14, 2017 | 6 | | Power of Attorney Download |
Apr 14, 2017 | 7 | | Mandatory Notice Download |
May 5, 2017 | 8 | | Notice of Deposition of Elena Massarotti Download |
May 9, 2017 | 9 | | Petitioner's Unopposed Motion For Pro Hac Vice Admission Of Charles B. Klein And Eimeric Reig-Plessis Download |
May 9, 2017 | 10 | | Petitioner's Updated Exhibit List (05 09 2017) Download |
Jul 10, 2017 | 11 | | Joint Motion to Dismiss Download |
Jul 18, 2017 | 12 | | Granting Motion for Pro Hac Vice Recognition of
Mr. Charles B. Klein and Mr. Eimeric Reig-Plessis
37 C.F.R. sec 42.10(c) Download |
Jul 18, 2017 | 13 | | Decision Institution of Inter Partes Review, Grant of Motion for Joinder, and Grant of Joint Motion to Dismiss Certain Challenges in the Petition Download |
Feb 22, 2018 | 14 | | IPR2016-01614 Final Written Decision Download |
Mar 24, 2017 | 1001 | | U.S. Patent 7,820,161 Download |
Mar 24, 2017 | 1002 | | Declaration of Elena Massarotti MD Download |
Mar 24, 2017 | 1003 | | Elena Massarotti CV Download |
Mar 24, 2017 | 1004 | | Second Declaration of Ronald F. van Vollenhoven, dated January 19, 2010 Download |
Mar 24, 2017 | 1005 | | Eisenberg letter to Genetech Oncology & IDEC Download |
Mar 24, 2017 | 1006 | | Gryn letter to Parker, dated May 6, 1998 Download |
Mar 24, 2017 | 1007 | | Saleh letter to Comprehensive Cancer Center, dated October 1, 1998 Download |
Mar 24, 2017 | 1008 | | Latov letter to Horvath, dated November 16, 1998 Download |
Mar 24, 2017 | 1009 | | Pestronk letter to Department of Neurology, dated October 12, 1998 Download |
Mar 24, 2017 | 1010 | | Looney letter to Duthcer dated January 15, 1999 Download |
Mar 24, 2017 | 1011 | | American Colelge of Rheumatology Subcommittee Download |
Mar 24, 2017 | 1012 | | T. Pincus & C.M. Stein, No Evidence of disease in rheumatoid arthritis Download |
Mar 24, 2017 | 1013 | | William Schwieterman FDA Conversation Download |
Mar 24, 2017 | 1014 | | Kremer, Methotrexate for Rheumatoid Arthritis Download |
Mar 24, 2017 | 1015 | | ODell, Methotrexate Use (1997) Download |
Mar 24, 2017 | 1016 | | Boers et al., The Lancet, 350.309-18 (1997) Download |
Mar 24, 2017 | 1017 | | Boers, World Health Organization Download |
Mar 24, 2017 | 1018 | | Felson American College of Rheumatology Download |
Mar 24, 2017 | 1019 | | Kremer, Combination Therapy with Biologic Agents in Rheumatoid Arthritis Download |
Mar 24, 2017 | 1020 | | Guidance for Industry Clinical Development Programs for Drugs Download |
Mar 24, 2017 | 1021 | | Weinblatt et al., New England Journal of Medicine Download |
Mar 24, 2017 | 1022 | | Maini et al., Arthritis & Rheumatism Download |
Mar 24, 2017 | 1023 | | First Declaration of Ronald F. van Vollenhoven, dated July 30, 2007 Download |
Mar 24, 2017 | 1024 | | IPR2015-00415 Patent Owner's Preliminary Response Download |
Mar 24, 2017 | 1025 | | Maloney Phase 1 Clinical Trial Using Escalating Single-Dose Infusion (1994) Download |
Mar 24, 2017 | 1026 | | Maloney IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy (1997) Download |
Mar 24, 2017 | 1027 | | WO 95.03770 Download |
Mar 24, 2017 | 1029 | | Maloney et al., IDEC-C2B8 (1997) Download |
Mar 24, 2017 | 1030 | | Edwards, The Predictable Effect of Small Immune Complexes Download |
Mar 24, 2017 | 1031 | | Edwards, The case for Killing Cells with ANTI-CD20 in RA Download |
Mar 24, 2017 | 1033 | | The University College London Hospitals, October 30, 1998 Letter Download |
Mar 24, 2017 | 1034 | | The Joint UCL,UCLH Committees on the Ethics of Human Research Download |
Mar 24, 2017 | 1035 | | Letter from the Medicines Control Agency to Edwards Download |
Mar 24, 2017 | 1036 | | Information for patients undergoing treatment of rheumatoid arthritis Download |
Mar 24, 2017 | 1037 | | Rituxan label 1997 Download |
Mar 24, 2017 | 1038 | | Kremer (1995) Download |
Mar 24, 2017 | 1039 | | Declaration by Jonathan Charles Wright Edwards Download |
Mar 24, 2017 | 1040 | | Moreland Etanercept Therapy in Rheumatoid Arthritis Download |
Mar 24, 2017 | 1041 | | Remicade Label 1998 Download |
Mar 24, 2017 | 1042 | | FDA, 64 Fed. Reg. 7898 Download |
Mar 24, 2017 | 1043 | | Buch, Updated consensus statemetn on the use of rituximab Download |
Mar 24, 2017 | 1044 | | Wendler, Rituximab in Practice Download |
Mar 24, 2017 | 1045 | | Edwards, Efficacy of B-Cell-Targeted Therapy (2004) Download |
Apr 7, 2017 | 1046 | | Klareskog, Double-Blind Randomised Controlled Trial Download |
Mar 24, 2017 | 1046 | | Klareskog, double-blind randomised controlled trial Download |
Apr 7, 2017 | 1046 | | Klareskog, Double-Blind Randomised Controlled Trial Download |
Mar 24, 2017 | 1047 | | Bathon, Comparison of Etanercept and Methotrexate (2000) Download |
Mar 24, 2017 | 1048 | | Gabriel, the Epidemiology of Rheumatoid Arthritis Download |
Mar 24, 2017 | 1049 | | Decision of the European Patent Office re-EP1179681 Download |
Mar 24, 2017 | 1051 | | Kalden, Rescue of DMARD Failure by Means of Monoclonal Antibodies Download |
Mar 24, 2017 | 1052 | | FDA, Rituxan Approval Letter, 97-0244 (November 26, 1997) Download |
Mar 24, 2017 | 1053 | | Drugs@FDA, FDA Applciation No. (BLA) 103705 Download |
Mar 24, 2017 | 1054 | | 1997 Form 10-K405.A filed by IDEC Pharmaceuticals Download |
Mar 24, 2017 | 1055 | | Internet Archive Capture of Genentech Website for Rituxan Download |
Mar 24, 2017 | 1056 | | Declaration from Internet Archive Download |
Mar 24, 2017 | 1057 | | ODell, Treatment of Rheumatoid Arthritis with Methotrexate Alone Download |
May 9, 2017 | 1058 | | Ex. 1058 - Declaration of Charles B. Klein ISO PHV Motion Download |
May 9, 2017 | 1059 | | Ex. 1059 - Declaration of Eimeric Reig-Plessis ISO PHV Motion Download |